PANITUMUMAB Side Effects

7023233-7 | Colitis, Diarrhoea, Hyperglycaemia, Leukopenia, Platelet Count Decreased, Renal Failure, Sepsis
on Sep 24, 2010 Male patient from UNITED STATES , 68 years of age, weighting 170.2 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: colitis, diarrhoea, hyperglycaemia, leukopenia, platelet count decreased, renal failure, sepsis (What is sepsis?). Panitumumab dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), MAGNESIUM (View Magnesium Review and Magnesium Label ). Patient was hospitalized.

7018719-5 | Hypophosphataemia
Patient was taking Panitumumab (View Usage). Patient had the following side effects: hypophosphataemia on Sep 21, 2010 from UNITED STATES Additional patient health information: Male patient , 47 years of age, weighting 286.6 lb, was diagnosed with oesophageal carcinoma and. Panitumumab dosage: . During the same period patient was treated with TAXOTERE (View Taxotere Review and Taxotere Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), CELEXA (View Celexa Review and Celexa Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), MINOCYCLINE HCL (View Minocycline Hcl Review and Minocycline Hcl Label ), ROXICET (View Roxicet Review and Roxicet Label ).

7016251-6 | Malignant Neoplasm Progression
Adverse event was reported on Sep 22, 2010 by a Female patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with neoplasm malignant and. Location: BELGIUM , 64 years of age, After Panitumumab was administered, patient had the following side effects: malignant neoplasm progression. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), DAFALGAN (View Dafalgan Review and Dafalgan Label ), DURAGESIC 100 (View Duragesic-100 Review and Duragesic-100 Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ). Patient was hospitalized.

7013575-3 | Diarrhoea, Gastrointestinal Infection
on Sep 16, 2010 Male patient from UNITED STATES , 55 years of age, weighting 162.3 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: diarrhoea, gastrointestinal infection. Panitumumab dosage: . During the same period patient was treated with TARCEVA (View Tarceva Review and Tarceva Label ), GEMZAR (View Gemzar Review and Gemzar Label ). Patient was hospitalized.


7010020-9 | Activated Partial Thromboplastin Time Abnormal, Lymphopenia, Pulmonary Embolism
on Sep 14, 2010 Male patient from UNITED STATES , 59 years of age, weighting 183.0 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). Patient had the following side effects: activated partial thromboplastin time abnormal, lymphopenia, pulmonary embolism (What is pulmonary embolism?). Panitumumab dosage: . During the same period patient was treated with TAXOTERE (View Taxotere Review and Taxotere Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

7001566-8 | Lymphopenia
Patient was taking Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: lymphopenia on Sep 16, 2010 from UNITED STATES Additional patient health information: Female patient , 68 years of age, weighting 221.8 lb, was diagnosed with oesophageal carcinoma and. Panitumumab dosage: . During the same period patient was treated with DOCETAXEL (View Docetaxel Review and Docetaxel Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), VERAPAMIL (View Verapamil Review and Verapamil Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), LIPITOR (View Lipitor Review and Lipitor Label ), CELEBREX (View Celebrex Review and Celebrex Label ), VITAMIN E (View Vitamin E Review and Vitamin E Label ). Patient was hospitalized.

6979518-3 | Rash
Adverse event was reported on Sep 10, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: 450 Mg Once Iv) was diagnosed with colon cancer and. Location: UNITED STATES , 78 years of age, weighting 167.6 lb, Patient experienced the following unwanted or unexpected effects: rash (What is rash?). Patient was hospitalized.

6977530-1 | Febrile Neutropenia, Hypokalaemia
on Sep 08, 2010 Male patient from , 54 years of age, weighting 187.4 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). Patient had the following side effects: febrile neutropenia, hypokalaemia. Panitumumab dosage: . During the same period patient was treated with DOCETAXEL (View Docetaxel Review and Docetaxel Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6969473-4 | Lymphopenia
on Sep 02, 2010 Male patient from UNITED STATES , 58 years of age, weighting 171.3 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: lymphopenia. Panitumumab dosage: . During the same period patient was treated with TAXOTERE (View Taxotere Review and Taxotere Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ), POTASSIUM PHOSPHATES (View Potassium Phosphates Review and Potassium Phosphates Label ), AZITHROMYCIN (View Azithromycin Review and Azithromycin Label ), DECADRON (View Decadron Review and Decadron Label ), HYCODAN (View Hycodan Review and Hycodan Label ).

6969463-1 | Acute Respiratory Distress Syndrome, Colitis, Diarrhoea, Dyspnoea, Endocarditis, Fatigue, Febrile Neutropenia, Hypoalbuminaemia, Hypocalcaemia
Patient was taking Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: acute respiratory distress syndrome, colitis, diarrhoea, dyspnoea, endocarditis (What is endocarditis?), fatigue, febrile neutropenia, hypoalbuminaemia, hypocalcaemia on Aug 27, 2010 from UNITED STATES Additional patient health information: Male patient , 64 years of age, weighting 233.0 lb, was diagnosed with oesophageal carcinoma and. Panitumumab dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ), NORCO (View Norco Review and Norco Label ). Patient was hospitalized.

6968654-3 | Acute Respiratory Failure
Adverse event was reported on Sep 01, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: UNITED KINGDOM , weighting 178.6 lb, Patient had the following side effects: acute respiratory failure. During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ). Patient was hospitalized.

6963708-X | Deep Vein Thrombosis, Haemoglobin Decreased, Upper Gastrointestinal Haemorrhage
on Aug 30, 2010 Male patient from UNITED STATES , 64 years of age, weighting 244.7 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: deep vein thrombosis (What is deep vein thrombosis?), haemoglobin decreased, upper gastrointestinal haemorrhage. Panitumumab dosage: . During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), TARCEVA (View Tarceva Review and Tarceva Label ), ARIXTRA (View Arixtra Review and Arixtra Label ). Patient was hospitalized.

6961813-5 | Lymphopenia
on Aug 26, 2010 Female patient from UNITED STATES , 68 years of age, weighting 221.8 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: lymphopenia. Panitumumab dosage: . During the same period patient was treated with DOCETAXEL (View Docetaxel Review and Docetaxel Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), VERAPAMIL (View Verapamil Review and Verapamil Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), LIPITOR (View Lipitor Review and Lipitor Label ), CELEBREX (View Celebrex Review and Celebrex Label ), VITAMIN E (View Vitamin E Review and Vitamin E Label ). Patient was hospitalized.

6961785-3 | Cardiogenic Shock, Cardiomyopathy, Dehydration, Respiratory Failure
Patient was taking Panitumumab (View Usage). Patient had the following side effects: cardiogenic shock, cardiomyopathy (What is cardiomyopathy?), dehydration, respiratory failure on Aug 27, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 264.3 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and. Panitumumab dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), LASIX (View Lasix Review and Lasix Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), IMODIUM (View Imodium Review and Imodium Label ), POTASSIUM (View Potassium Review and Potassium Label ), MAGNESIUM (View Magnesium Review and Magnesium Label ), FERROUS SULFATE (View Ferrous Sulfate Review and Ferrous Sulfate Label ). Patient was hospitalized.

6959071-0 | Atrial Fibrillation
Adverse event was reported on Aug 24, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with neoplasm malignant and. Location: CANADA , weighting 181.9 lb, After Panitumumab was administered, patient had the following side effects: atrial fibrillation (What is atrial fibrillation?). During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), ALTACE (View Altace Review and Altace Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), ASPIRIN (View Aspirin Review and Aspirin Label ), LIPITOR (View Lipitor Review and Lipitor Label ). Patient was hospitalized.

6957870-2 | Acute Respiratory Failure
on Aug 24, 2010 Male patient from UNITED KINGDOM , weighting 178.6 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: acute respiratory failure. Panitumumab dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ). Patient was hospitalized.

6943601-9 | Lymphopenia
on Aug 18, 2010 Male patient from UNITED STATES , 58 years of age, weighting 171.3 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). Patient had the following side effects: lymphopenia. Panitumumab dosage: . During the same period patient was treated with TAXOTERE (View Taxotere Review and Taxotere Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ).

6939100-0 | Diarrhoea
Patient was taking Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: diarrhoea on Aug 19, 2010 from UNITED KINGDOM Additional patient health information: Male patient , weighting 150.6 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and. Panitumumab dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ). Patient was hospitalized.

6937543-2 | Pulmonary Embolism, Thrombosis
Adverse event was reported on Aug 16, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with pancreatic carcinoma and. Location: UNITED STATES , 48 years of age, weighting 205.0 lb, Patient experienced the following unwanted or unexpected effects: pulmonary embolism (What is pulmonary embolism?), thrombosis. During the same period patient was treated with GEMZAR (View Gemzar Review and Gemzar Label ), TARCEVA (View Tarceva Review and Tarceva Label ), COUMADIN (View Coumadin Review and Coumadin Label ), LOVENOX (View Lovenox Review and Lovenox Label ). Patient was hospitalized.

6937539-0 | Hypophosphataemia
on Aug 16, 2010 Male patient from UNITED STATES , 47 years of age, weighting 286.6 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). Patient had the following side effects: hypophosphataemia. Panitumumab dosage: . During the same period patient was treated with TAXOTERE (View Taxotere Review and Taxotere Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), CELEXA (View Celexa Review and Celexa Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), MINOCYCLINE HCL (View Minocycline Hcl Review and Minocycline Hcl Label ), ROXICET (View Roxicet Review and Roxicet Label ).

6936699-5 | Gastrointestinal Anastomotic Leak, Hypokalaemia, Neutropenia
on Aug 13, 2010 Female patient from UNITED STATES , 76 years of age, weighting 145.5 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: gastrointestinal anastomotic leak, hypokalaemia, neutropenia. Panitumumab dosage: . During the same period patient was treated with DOCETAXEL (View Docetaxel Review and Docetaxel Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6936693-4 | Febrile Neutropenia, Hypokalaemia
Patient was taking Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia, hypokalaemia on Aug 13, 2010 from Additional patient health information: Male patient , 54 years of age, weighting 187.4 lb, was diagnosed with oesophageal carcinoma and. Panitumumab dosage: . During the same period patient was treated with DOCETAXEL (View Docetaxel Review and Docetaxel Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

6934700-6 | Alanine Aminotransferase Abnormal, Aspartate Aminotransferase Abnormal, Dehydration, Dysphagia, Embolism Arterial, Haemoglobin Abnormal, Lymphopenia, Oesophageal Perforation, Oesophagitis
Adverse event was reported on Aug 13, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with oesophageal carcinoma and. Location: UNITED STATES , 46 years of age, weighting 177.5 lb, Patient had the following side effects: alanine aminotransferase abnormal, aspartate aminotransferase abnormal, dehydration, dysphagia, embolism arterial, haemoglobin abnormal, lymphopenia, oesophageal perforation, oesophagitis. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ). Patient was hospitalized.

6934498-1 | Lymphopenia
on Aug 12, 2010 Female patient from UNITED STATES , 68 years of age, weighting 221.8 lb, was diagnosed with oesophageal carcinoma and was treated with Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: lymphopenia. Panitumumab dosage: . During the same period patient was treated with DOCETAXEL (View Docetaxel Review and Docetaxel Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), SYNTHROID (View Synthroid Review and Synthroid Label ), VERAPAMIL (View Verapamil Review and Verapamil Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), LIPITOR (View Lipitor Review and Lipitor Label ), CELEBREX (View Celebrex Review and Celebrex Label ), VITAMIN E (View Vitamin E Review and Vitamin E Label ). Patient was hospitalized.

6933131-2 | Blood Alkaline Phosphatase, Fatigue, Hepatic Failure, Hyponatraemia, Platelet Count, Pyrexia
on Aug 11, 2010 Female patient from UNITED STATES , 78 years of age, weighting 123.7 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: blood alkaline phosphatase, fatigue, hepatic failure, hyponatraemia, platelet count, pyrexia. Panitumumab dosage: . During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), TARCEVA (View Tarceva Review and Tarceva Label ). Patient was hospitalized.

6929200-3 | Diarrhoea, Endocarditis, Febrile Neutropenia, Nausea, Oesophagitis, Renal Failure
Patient was taking Panitumumab (View Usage). Patient had the following side effects: diarrhoea, endocarditis (What is endocarditis?), febrile neutropenia, nausea (What is nausea?), oesophagitis, renal failure on Aug 09, 2010 from UNITED STATES Additional patient health information: Male patient , 64 years of age, weighting 233.0 lb, was diagnosed with oesophageal carcinoma and. Panitumumab dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ), NORCO (View Norco Review and Norco Label ). Patient was hospitalized.

6928348-7 | Anaemia, Deep Vein Thrombosis, Malignant Pleural Effusion
Adverse event was reported on Aug 09, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: UNITED STATES , weighting 157.2 lb, After Panitumumab was administered, patient had the following side effects: anaemia, deep vein thrombosis (What is deep vein thrombosis?), malignant pleural effusion. During the same period patient was treated with DECITABINE (View Decitabine Review and Decitabine Label ), CYCLOBENZAPRINE (View Cyclobenzaprine Review and Cyclobenzaprine Label ), DICYCLOMINE HYDROCHLORIDE (View Dicyclomine Hydrochloride Review and Dicyclomine Hydrochloride Label ), DOCUSATE SODIUM (View Docusate Sodium Review and Docusate Sodium Label ), DOXYCYCLINE (View Doxycycline Review and Doxycycline Label ), EMLA (View Emla Review and Emla Label ), LEXAPRO (View Lexapro Review and Lexapro Label ), LOVENOX (View Lovenox Review and Lovenox Label ). Patient was hospitalized.

6922195-8 | Cardiogenic Shock, Cardiomyopathy, Dehydration, Respiratory Failure
on Aug 05, 2010 Female patient from UNITED STATES , weighting 264.3 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: cardiogenic shock, cardiomyopathy (What is cardiomyopathy?), dehydration, respiratory failure. Panitumumab dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), LASIX (View Lasix Review and Lasix Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), IMODIUM (View Imodium Review and Imodium Label ), POTASSIUM (View Potassium Review and Potassium Label ), MAGNESIUM (View Magnesium Review and Magnesium Label ), FERROUS SULFATE (View Ferrous Sulfate Review and Ferrous Sulfate Label ). Patient was hospitalized.

6922182-X | Delirium, Device Related Infection, Febrile Neutropenia, Hepatic Failure, Hepatitis Viral, Ischaemic Hepatitis, Pancytopenia, Transaminases Increased
on Aug 04, 2010 Male patient from UNITED STATES , weighting 150.1 lb, was diagnosed with squamous cell carcinoma and was treated with Panitumumab (View Usage). Patient had the following side effects: delirium, device related infection, febrile neutropenia, hepatic failure, hepatitis viral, ischaemic hepatitis, pancytopenia, transaminases increased. Panitumumab dosage: . During the same period patient was treated with TAXOL (View Taxol Review and Taxol Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), ATIVAN (View Ativan Review and Ativan Label ), ALKALOL (View Alkalol Review and Alkalol Label ), CLINDAGEL (View Clindagel Review and Clindagel Label ), CLOBETASOL PROPIONATE (View Clobetasol Propionate Review and Clobetasol Propionate Label ), COMPAZINE (View Compazine Review and Compazine Label ). Patient was hospitalized.

6917824-9 | Dehydration, Diarrhoea, Dyspnoea, Hyponatraemia, Hypotension, Hypoxia
Patient was taking Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: dehydration, diarrhoea, dyspnoea, hyponatraemia, hypotension, hypoxia on Aug 02, 2010 from UNITED STATES Additional patient health information: Male patient , 71 years of age, weighting 147.5 lb, was diagnosed with pancreatic carcinoma and. Panitumumab dosage: . During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), TARCEVA (View Tarceva Review and Tarceva Label ). Patient was hospitalized.

6914674-4 | Delirium, Device Related Infection, Febrile Neutropenia, Hepatic Failure, Hepatitis Viral, Hypotension, Ischaemic Hepatitis, Pancytopenia
Adverse event was reported on Aug 05, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: 2.5 Mg/kg/iv/wkly) was diagnosed with head and neck cancer (What is head and neck cancer?) and. Location: UNITED STATES , 48 years of age, weighting 150.0 lb, Patient experienced the following unwanted or unexpected effects: delirium, device related infection, febrile neutropenia, hepatic failure, hepatitis viral, hypotension, ischaemic hepatitis, pancytopenia. During the same period patient was treated with TAXOL (20 Mg/m2/iv/wkly) (View Taxol Review and Taxol Label ), CARBOPLATIN (1.5 Auc/iv/wkly) (View Carboplatin Review and Carboplatin Label ), ATIVAN (View Ativan Review and Ativan Label ), ALKALOL (View Alkalol Review and Alkalol Label ), CLINDAGEL (View Clindagel Review and Clindagel Label ), CLOBETASOL PROPIONATE (View Clobetasol Propionate Review and Clobetasol Propionate Label ), COMPAZINE (View Compazine Review and Compazine Label ). Patient was hospitalized.

6896314-6 | Embolism Arterial, Hyperglycaemia, Thrombosis
on Jul 23, 2010 Male patient from UNITED STATES , 55 years of age, weighting 235.5 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). Patient had the following side effects: embolism arterial, hyperglycaemia, thrombosis. Panitumumab dosage: . During the same period patient was treated with GEMZAR (View Gemzar Review and Gemzar Label ), ERLOTINIB HYDROCHLORIDE (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ). Patient was hospitalized.

6885278-7 | Fatigue, Hyponatraemia, Pyrexia
on Jul 22, 2010 Female patient from UNITED STATES , 78 years of age, weighting 123.7 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: fatigue, hyponatraemia, pyrexia. Panitumumab dosage: . During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), TARCEVA (View Tarceva Review and Tarceva Label ). Patient was hospitalized.

6885217-9 | Cerebral Ischaemia, Decubitus Ulcer, Haemoglobin Decreased, Pyrexia
Patient was taking Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral ischaemia, decubitus ulcer, haemoglobin decreased, pyrexia on Jul 23, 2010 from UNITED STATES Additional patient health information: Male patient , 71 years of age, weighting 212.3 lb, was diagnosed with pancreatic carcinoma and. Panitumumab dosage: . During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), ERLOTINIB HYDROCHLORIDE (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), CARDURA (View Cardura Review and Cardura Label ), CIPROFLOXACIN (View Ciprofloxacin Review and Ciprofloxacin Label ), COREG (View Coreg Review and Coreg Label ), COUMADIN (View Coumadin Review and Coumadin Label ), MAGNESIUM OXIDE (View Magnesium Oxide Review and Magnesium Oxide Label ), PRINIVIL (View Prinivil Review and Prinivil Label ). Patient was hospitalized.

6879952-6 | Dehydration, Diarrhoea, Hyponatraemia, Hypophosphataemia, Hypotension
Adverse event was reported on Jul 22, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with pancreatic carcinoma and. Location: UNITED STATES , 71 years of age, weighting 147.5 lb, Patient had the following side effects: dehydration, diarrhoea, hyponatraemia, hypophosphataemia, hypotension. During the same period patient was treated with GEMCITABINE (View Gemcitabine Review and Gemcitabine Label ), TARCEVA (View Tarceva Review and Tarceva Label ). Patient was hospitalized.

6877191-6 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Bacteraemia, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Dehydration, Diarrhoea, Dizziness
on Jul 22, 2010 Female patient from UNITED STATES , 66 years of age, weighting 259.5 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, bacteraemia, blood alkaline phosphatase increased, blood bilirubin increased, dehydration, diarrhoea, dizziness (What is dizziness?). Panitumumab dosage: . During the same period patient was treated with TARCEVA (View Tarceva Review and Tarceva Label ), GEMZAR (View Gemzar Review and Gemzar Label ), LOMOTIL (View Lomotil Review and Lomotil Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), METFORMIN HCL (View Metformin Hcl Review and Metformin Hcl Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ). Patient was hospitalized.

6875054-3 | Fatigue, Hyponatraemia, Pyrexia
on Jul 16, 2010 Female patient from UNITED STATES , 78 years of age, weighting 123.7 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: fatigue, hyponatraemia, pyrexia. Panitumumab dosage: . During the same period patient was treated with GEMCITABINE HCL (View Gemcitabine Hcl Review and Gemcitabine Hcl Label ), TARCEVA (View Tarceva Review and Tarceva Label ). Patient was hospitalized.

6857622-8 | Neutropenia
Patient was taking Panitumumab (View Usage). Patient had the following side effects: neutropenia on Jul 14, 2010 from UNITED KINGDOM Additional patient health information: Male patient , weighting 168.4 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and. Panitumumab dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ). Patient was hospitalized.

6851206-3 | Cardiogenic Shock, Cardiomyopathy, Dehydration, Respiratory Failure
Adverse event was reported on Jul 12, 2010 by a Female patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: UNITED STATES , weighting 264.3 lb, After Panitumumab was administered, patient had the following side effects: cardiogenic shock, cardiomyopathy (What is cardiomyopathy?), dehydration, respiratory failure. During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), LASIX (View Lasix Review and Lasix Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), IMODIUM (View Imodium Review and Imodium Label ), POTASSIUM CHLORIDE (View Potassium Chloride Review and Potassium Chloride Label ), MAGNESIUM (View Magnesium Review and Magnesium Label ), FERROUS SULFATE (View Ferrous Sulfate Review and Ferrous Sulfate Label ). Patient was hospitalized.

6835746-9 | Ascites, Oedema Peripheral
on Jul 08, 2010 Male patient from UNITED KINGDOM , weighting 136.7 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: ascites, oedema peripheral. Panitumumab dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ). Patient was hospitalized.

6833314-6 | Dehydration, Diarrhoea, Nausea, Stomatitis
on Jul 06, 2010 Female patient from UNITED STATES , 69 years of age, weighting 169.8 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). Patient had the following side effects: dehydration, diarrhoea, nausea (What is nausea?), stomatitis. Panitumumab dosage: . During the same period patient was treated with FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ). Patient was hospitalized.

6822267-2 | Ascites, Oedema Peripheral
Patient was taking Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: ascites, oedema peripheral on Jul 06, 2010 from UNITED KINGDOM Additional patient health information: Male patient , weighting 136.7 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and. Panitumumab dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ). Patient was hospitalized.

6818713-0 | Alanine Aminotransferase Abnormal, Aspartate Aminotransferase Abnormal, Dehydration, Dysphagia, Embolism Arterial, Haemoglobin Abnormal, Lymphopenia, Oesophageal Perforation, Oesophagitis
Adverse event was reported on Jun 30, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with oesophageal carcinoma and. Location: UNITED STATES , 46 years of age, weighting 163.4 lb, Patient experienced the following unwanted or unexpected effects: alanine aminotransferase abnormal, aspartate aminotransferase abnormal, dehydration, dysphagia, embolism arterial, haemoglobin abnormal, lymphopenia, oesophageal perforation, oesophagitis. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), DOCETAXEL (View Docetaxel Review and Docetaxel Label ). Patient was hospitalized.

6817360-4 | Cardiac Arrest
on Jul 02, 2010 Female patient from UNITED KINGDOM , 69 years of age, was diagnosed with colorectal cancer (What is colorectal cancer?) and was treated with Panitumumab (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?). Panitumumab dosage: .

6815704-0 | Abdominal Pain, Fatigue, Haemoglobin Decreased, Hyperbilirubinaemia, Hypophosphataemia, Hypotension, Muscular Weakness, Sepsis, Upper Gastrointestinal Haemorrhage
on Jun 24, 2010 Male patient from UNITED STATES , 79 years of age, weighting 143.3 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: abdominal pain (What is abdominal pain?), fatigue, haemoglobin decreased, hyperbilirubinaemia, hypophosphataemia, hypotension, muscular weakness, sepsis (What is sepsis?), upper gastrointestinal haemorrhage. Panitumumab dosage: . During the same period patient was treated with FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), GEMCITABINE HYDROCHLORIDE (View Gemcitabine Hydrochloride Review and Gemcitabine Hydrochloride Label ). Patient was hospitalized.

6796101-3 | Cerebrovascular Accident
Patient was taking Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: cerebrovascular accident on Jun 21, 2010 from ITALY Additional patient health information: Male patient , weighting 191.8 lb, was diagnosed with colorectal cancer (What is colorectal cancer?) and. Panitumumab dosage: . During the same period patient was treated with OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ), LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), KYTRIL (View Kytril Review and Kytril Label ), PARIET (View Pariet Review and Pariet Label ), LEVOTHYROXINE SODIUM (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), HUMALOG (View Humalog Review and Humalog Label ). Patient was hospitalized and became disabled.

6787949-X | Alanine Aminotransferase Increased, Blood Calcium Decreased, Blood Magnesium Increased, Blood Sodium Decreased, C-reactive Protein Increased, Dehydration, Infection, Neutropenic Sepsis, Neutrophil Count Decreased
Adverse event was reported on Jun 16, 2010 by a Male patient taking Panitumumab (View Usage) (Dosage: ) was diagnosed with colorectal cancer (What is colorectal cancer?) and. Location: UNITED KINGDOM , weighting 172.8 lb, Patient had the following side effects: alanine aminotransferase increased, blood calcium decreased, blood magnesium increased, blood sodium decreased, c-reactive protein increased, dehydration, infection (What is infection?), neutropenic sepsis, neutrophil count decreased. During the same period patient was treated with IRINOTECAN (View Irinotecan Review and Irinotecan Label ), FLOXACILLIN SODIUM (View Floxacillin Sodium Review and Floxacillin Sodium Label ). Patient was hospitalized.

6786157-6 | Hyperbilirubinaemia, Small Intestinal Haemorrhage
on Jun 16, 2010 Male patient from UNITED STATES , 62 years of age, weighting 209.4 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). After Panitumumab was administered, patient had the following side effects: hyperbilirubinaemia, small intestinal haemorrhage. Panitumumab dosage: . During the same period patient was treated with GEMCITABINE HCL (View Gemcitabine Hcl Review and Gemcitabine Hcl Label ), TARCEVA (View Tarceva Review and Tarceva Label ). Patient was hospitalized.

6785087-3 | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Blood Bilirubin Increased, Blood Calcium Decreased, Blood Sodium Decreased, Blood Urea Increased, Dehydration, Diarrhoea
on Jun 17, 2010 Female patient from UNITED STATES , 66 years of age, weighting 259.5 lb, was diagnosed with pancreatic carcinoma and was treated with Panitumumab (View Usage). Patient experienced the following unwanted or unexpected effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood sodium decreased, blood urea increased, dehydration, diarrhoea. Panitumumab dosage: . During the same period patient was treated with TARCEVA (View Tarceva Review and Tarceva Label ), GEMZAR (View Gemzar Review and Gemzar Label ), LOMOTIL (View Lomotil Review and Lomotil Label ), GLIMEPIRIDE (View Glimepiride Review and Glimepiride Label ), METFORMIN (View Metformin Review and Metformin Label ), LISINOPRIL (View Lisinopril Review and Lisinopril Label ), AUGMENTIN '125' (View Augmentin '125' Review and Augmentin '125' Label ). Patient was hospitalized.

6775628-4 | Decreased Appetite, Dehydration, Dizziness, Dyspnoea, Fatigue, Hyperglycaemia, Hypotension, Lymphopenia, Muscular Weakness
Patient was taking Panitumumab (View Usage). Patient had the following side effects: decreased appetite, dehydration, dizziness (What is dizziness?), dyspnoea, fatigue, hyperglycaemia, hypotension, lymphopenia, muscular weakness on Jun 11, 2010 from UNITED STATES Additional patient health information: Male patient , 75 years of age, weighting 154.3 lb, was diagnosed with pancreatic carcinoma and. Panitumumab dosage: . During the same period patient was treated with FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), GEMCITABINE HCL (View Gemcitabine Hcl Review and Gemcitabine Hcl Label ). Patient was hospitalized.